ICU Medical, Incorporated (OQ:ICUI)

Business Focus: Medical Equipment, Supplies & Distribution

Sector:  Healthcare Industry:  Medical Equipment, Supplies & Distribution
See Regulatory Filings on SEC
Company Contact
Address: 951 Calle Amanecer
Tel: 1-646-2771254
IR: See website
Key People
Vivek Jain
Chairman of the Board, Chief Executive Officer, Director
Brian Bonnell
Chief Financial Officer, Treasurer
Christian B. Voigtlander
Chief Operating Officer
Virginia Sanzone
Vice President, General Counsel, Secretary
Tom L. McCall
Corporate Vice President - Marketing and Communications, General Manager - Critical Care
Alison D. Burcar
Corporate Vice President, Product Strategy for IV Consumables
Business Overview
ICU Medical, Inc. is engaged in the development, manufacture and sales of medical devices used in infusion therapy, oncology and critical care applications. The Company's product line includes needlefree connection devices, custom infusion sets, closed system transfer devices (CSTD) for the handling of hazardous drugs, advanced sensor catheters, needlefree closed blood sampling systems, disposable pressure transducer systems and hemodynamic monitoring systems. The primary critical care products it manufactures are Hemodynamic Monitoring Systems, SafeSet Closed Blood Sampling and Conservation System, Transpac Consumable Blood Pressure Transducers and Other Critical Care Products. The primary oncology products it manufactures are ChemoLock Needlefree CSTD, ChemoClave Needlefree CSTD and Diana Hazardous Drug Compounding System. As of December 31, 2016, its products were used in acute care hospitals and ambulatory clinics in more than 65 countries throughout the world.
Financial Overview
For the fiscal year ended 31 December 2019, ICU Medical, Incorporated revenues decreased 10% to $1.27B. Net income before extraordinary items increased from $29.6M to $101M. Revenues reflect IV Solutions segment decrease of 18% to $415M, Infusion Systems segment decrease of 8% to $328.3M, United States segment decrease of 12% to $923.3M, EMEA segment decrease of 3% to $130.5M.
Employees: 8,000 as of Dec 31, 2019
Reporting Currency: U.S. Dollars
Enterprise value: $3,797M as of Dec 31, 2019
Annual revenue (TTM): $1,266M as of Dec 31, 2019
EBITDA (TTM): $270.67M as of Dec 31, 2019
Net annual income (TTM): $101.04M as of Dec 31, 2019
Free cash flow (TTM): -$4.12M as of Dec 31, 2019
Net Debt Last Fiscal Year: N/A
Shares outstanding: 20,774,907 as of Jan 31, 2020
Index Membership: S&P 400 Mid Cap
TTM: Trailing Twelve Months
EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization